Helen Floersh

Private equity dollars are flowing toward clinical trial sites as industry conditions demand larger site networks, PitchBook's analysis of first quarter 2024 deal activity shows.

GLP-1 drugs like Eli Lilly's Zepbound and Novo Nordisk's Wegovy work to address obesity—as long as a patient keeps taking them.

Terns Pharmaceuticals' prediction that its shelved metabolic dysfunction-associated steatohepatitis (MASH) drug TERN-501 could be effective against

A new association involving major players in Big Pharma is working to establish best industry practices for handling patients' biological samples, or biospecimen, during clinical trials.

As trial sponsors attempt to recruit more subjects from diverse racial and ethnic backgrounds, some are finding themselves impeded by a symptom of a long-standing disease in American medicine: mist

A new gene editing technique derived from bacterial “jumping genes” can add, remove, recombine and invert DNA sequences, potentially overcoming some of the limitations of CRISPR.

Contract research organizations aiming to get into the decentralized trials game in the U.S. may find the biggest opportunity in the Great Plains

Contract research organization Allucent has been chosen as a partner for the U.S. Biomedical Advanced Research and Development Authority's (BARDA) new

Clinical trial geography has undergone a major shift in the past five years, with China's share of the world's trials jumping nearly 60% amid declines

A $21 million public-private project led by the Foundation for the National Institutes of Health (FNIH) will see government agencies, nonprofits